

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application of | RECEIVED |) |
|-----------------------------------------|-------------------------------|------|
| TSCHOPE et al. | OCT 1 5 2003 | |
| Serial No. 09/508,510 | Examiner: PTECA CENTER 1600/2 | 2900 |
| Filed: May 26, 2000 |) Group Art Unit: 1646 | |
| For: LIQUID INTERFERON-BETA FORMULATION |)) | |

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,

Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application.

The publications are listed on the attached form PTO-1449.

Each item of information contained in this information disclosure statement was first cited in communications from a foreign patent office in a counterpart foreign application. The communications were received by counsel not more than three months prior to the filing of this statement. To facilitate the Examiner's understanding of the possible relevance of the references, Applicants are submitting a copy of the Opposition papers in which the references were cited. One of the items

10/10/2003 MDANTE1 00000032 022135 09508510

01 FC:1806

180.00 DA

Serial No. 09/508,510 Inventor: TSCHOPE et al.

(Opposition of Bioceuticals Arzneimittel AG) is in the German language and Applicants do not at this time have an English translation. It is Applicants understanding that the Patent Office may have access to translation services through the Scientific library, however, if the Examiner requests the Applicant's representative will inquire as to the availability of an English language version.

Since this Information Disclosure Statement is being filed after the issuance of a final Office Action, it is requested that the petition fee in the amount of \$180.00 be charged to Deposit ~Account No. 02-2135 to cover the government surcharge for submission and consideration of the Information Disclosure Statement.

The Commissioner is hereby authorized to charge additional fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck, Customer No. 6449.

Respectfully submitted,

Βv

Michael J. Moran

Attorney for Applicants Registration No. 42,013

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

| OCT 0 7 2003 & | | | | | İ | Complete if Known | | | | | | | | |
|------------------------------|--------------|---------------------|-----------------|--------------------------------------|----------|-------------------|------------------------------------|-----------------------------------------------------------------|----------------------------------|--------------------------------------------------|---------|--|--|--|
| <u> </u> | | | | App | lication | on Nu | mber | 09/508,510 | | | | | | |
| NATION DISCLOSURE | | | | | Filin | g Da | te | , | May 26, 2000 | RECEIVE | ם | | | |
| STATEMENT BY APPLICANT | | | | Firs | t Nan | ned In | ventor | May 26, 2000 RECEIVED TSCHOPE et al. 1646 007 1 5 2003 | | | | | | |
| | | | | | Gro | up Ar | t Unit | ** ** - | 1646 | | | | | |
| • | | | | | Exa | mine | r Nam | ie | P. Mertz | ECH CENTER 1600/2 | וחמ | | | |
| Sheet | 1 | | of | 2 | Atto | rney | Dock | et Number | 2923-495 | | | | | |
| | | | | | U.S. P | ATE | NT DO | CUMENTS | | | | | | |
| | | U | .S. Pate | ent Docum | ent | | | | | Data of Bublication | | | | |
| Examiner Cite Initials* No.1 | | | | | ind Coo | | | | entee or Applicant d Document | Date of Publication of Cited Document MM-DD-YYYY | | | | |
| | | <u> </u> | | | | | | | | | | | | |
| | | | | <u> </u> | | | | | | | | | | |
| | - | | | | | | | · | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | · · | | | | | | | | | | |
| | | | | | | • | | | ••• | | | | | |
| | | | - | | | | | | | | | | | |
| | 1 | | | F | OREIG | N PA | TENT | DOCUMEN | TS | | | | | |
| | | | Foreig | n Patent D | ocumer | nt | | | *** | Date of Publication of | | | | |
| Examiner Initials* | Cite No.1 | Office ³ | | Kind ⁵ Code (if known) | | | tentee of Applicant ed Document | Cited Document MM-DD-YYYY | T | | | | | |
| | A1 | WIPO | WIPO WO89/02750 | | | Cetus Corporation | | 04-06-1989 | | | | | | |
| | A2 | EPO | 0 284 | 249 | | _ _ | \1 | Interferon S | Services, Inc. | 09-28-1988 | | | | |
| | A3 | WIPO WO92/15614 | | | | A1 | | Chiron Opthalmics, Inc. | | 09-17-1992 | | | | |
| | | | | | | | | | | | \perp | | | |
| | | | | | | | | | | | \perp | | | |
| | | | | | | | | | | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached:

| OIP. E | 3 | | | | | | | _ | | | |
|------------------------|----|-------------------|--------------------------------------------------------------------------------------------------|---------------------------------------|-------------------------------|---------------------|---------------------------|---|--|--|--|
| ort 0 7 2003 2 | | Complete if Known | | | | | | | | | |
| 5 | | | Application Number | 09/508,510 | 09/508,510 | | | | | | |
| INFORMATION DISCLOSURE | | Filing Date | May 26, 2000 RECEIVED | | | | | | | | |
| STATEMENT BY APPLICANT | | | ANI | First Named Inventor | TSCHOPE 6 | | | | | | |
| | | | | | Group Art Unit | 1646 | E403 | | | | |
| | | | | | Examiner Name | TECH CENTER 1600/29 | 00 | | | | |
| Sheet | 2 | | of | 2 | Attorney Docket Number | 2923-495 | | | | | |
| | | | | NON PA | TENT LITERATURE DOCU | MENTS | | | | | |
| Examiner Initials* | | | | | | | | | | | |
| | A4 | Abst | ract/Figur | e, EMBL R | esearch Reports, Table of C | ontents (1 pag | ge) 2001. | | | | |
| | A5 | "Opp 2003 | | f Bioceutica | als Arzneimittel AG" to EP AF | PN 98950074.9 | 9: July 4, 2003; July 31, | | | | |
| | A6 | | "Opposition of Intellectual Property Services" to EP APN 98950074.9: July 4, 2003; July 10, 2003 | | | | | | | | |
| | | | | | | | | | | | |
| | | | | <u></u> | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | • | | | |
| | | | | , | | | - | | | | |
| | | | | | | | | | | | |
| | | | | - | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | ** | | | | | | | |
| Examiner Signature | | . • | - | · · · · · · · · · · · · · · · · · · · | | Date Considered | | - | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.